AIRLINK 69.40 Decreased By ▼ -3.66 (-5.01%)
BOP 4.90 Decreased By ▼ -0.19 (-3.73%)
CNERGY 4.24 Decreased By ▼ -0.13 (-2.97%)
DFML 31.66 Decreased By ▼ -0.79 (-2.43%)
DGKC 76.82 Increased By ▲ 1.33 (1.76%)
FCCL 19.97 Increased By ▲ 0.45 (2.31%)
FFBL 34.93 Decreased By ▼ -1.22 (-3.37%)
FFL 9.12 Decreased By ▼ -0.10 (-1.08%)
GGL 9.80 Decreased By ▼ -0.05 (-0.51%)
HBL 112.66 Decreased By ▼ -4.04 (-3.46%)
HUBC 132.80 Increased By ▲ 0.11 (0.08%)
HUMNL 6.95 Decreased By ▼ -0.15 (-2.11%)
KEL 4.19 Decreased By ▼ -0.22 (-4.99%)
KOSM 4.25 Decreased By ▼ -0.15 (-3.41%)
MLCF 36.45 Increased By ▲ 0.25 (0.69%)
OGDC 132.94 Decreased By ▼ -0.56 (-0.42%)
PAEL 22.50 Decreased By ▼ -0.10 (-0.44%)
PIAA 24.20 Decreased By ▼ -1.81 (-6.96%)
PIBTL 6.46 Decreased By ▼ -0.09 (-1.37%)
PPL 116.40 Increased By ▲ 1.09 (0.95%)
PRL 25.88 Decreased By ▼ -0.75 (-2.82%)
PTC 13.03 Decreased By ▼ -1.07 (-7.59%)
SEARL 51.95 Decreased By ▼ -1.50 (-2.81%)
SNGP 67.50 Increased By ▲ 0.25 (0.37%)
SSGC 10.54 Decreased By ▼ -0.16 (-1.5%)
TELE 8.23 Decreased By ▼ -0.19 (-2.26%)
TPLP 10.79 Increased By ▲ 0.04 (0.37%)
TRG 59.21 Decreased By ▼ -4.66 (-7.3%)
UNITY 25.14 Increased By ▲ 0.02 (0.08%)
WTL 1.27 No Change ▼ 0.00 (0%)
BR100 7,391 Decreased By -70.2 (-0.94%)
BR30 23,921 Decreased By -250.4 (-1.04%)
KSE100 70,683 Decreased By -419.1 (-0.59%)
KSE30 23,253 Decreased By -142 (-0.61%)

Widespread COVID-19 vaccinations not expected until mid-2021: WHO

  • None of the candidate vaccines in advanced clinical trials so far has demonstrated a "clear signal" of efficacy at the level of at least 50% sought by the WHO
Published September 4, 2020

The World Health Organization does not expect widespread vaccinations against COVID-19 until the middle of next year, a spokeswoman said on Friday, stressing the importance of rigourous checks on their effectiveness and safety.

None of the candidate vaccines in advanced clinical trials so far has demonstrated a "clear signal" of efficacy at the level of at least 50% sought by the WHO, spokeswoman Margaret Harris said.

Russia granted regulatory approval to a COVID-19 vaccine in August after less than two months of human testing, prompting some Western experts to question its safety and efficacy.

U.S. public health officials and Pfizer Inc said on Thursday a vaccine could be ready for distribution as soon as late October. That would be just ahead of the U.S. election on Nov. 3 in which the pandemic is likely to be a major factor among voters deciding whether President Donald Trump wins a second term.

"We are really not expecting to see widespread vaccination until the middle of next year," Harris told a U.N. briefing in Geneva.

"This phase 3 must take longer because you need to see how truly protective the vaccine is and you also need to see how safe it is," she added. This referred to the phase in vaccine research where large clinical trials among people are conducted. Harris did not refer to any specific vaccine candidate.

Comments

Comments are closed.